Study Summary
This trial is testing if a lower dose of Decitabine and venetoclax can kill cancer cells in people with myeloid malignancies while causing less damage to normal cells.
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: 12 months
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Single Arm
1 of 1
Experimental Treatment
33 Total Participants · 1 Treatment Group
Primary Treatment: Decitabine · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What potential risks are associated with Decitabine treatment?
"Our team assesses that Decitabine possesses an adequate degree of safety, as evidenced by its rating of 2. This implies there is some research indicating the drug's security but no studies demonstrating its efficacy in treating a condition." - Anonymous Online Contributor
Are there any vacancies for this clinical research initiative?
"The clinicaltrials.gov database confirms that this trial, which was first advertised on March 23rd 2022 is actively recruiting for participants. This information was last updated on July 22nd the same year." - Anonymous Online Contributor
What is the participant capacity for this experiment?
"Indeed, the data hosted on clinicaltrials.gov shows that this medical study is presently enrolling individuals. This trial was initially posted on March 23rd 2022 and has since been modified as recently as July 22nd 2022 - 33 patients are sought from a single site." - Anonymous Online Contributor